Financial Performance1Q25 group results beat expectations, with group revenues declining a more modest 6% compared to consensus expectations of a 14% decline.
Market PositionSublocade retains a dominant market share with approximately 80% share within the cohort for buprenorphine-based LAI and 60% share of LAI-naive patients.
Operational EfficiencyThe company achieved significant opex savings, contributing to the group sales beat expectations by 9%, gross margin by 10%, and adj. EBIT by over 40%.